Unlocking higher yields across a range of biologics at significantly lower costs to you, our patented fully-connected continuous manufacturing™ (FCCM™) platform represents the pinnacle of our ongoing commitment to innovation.
EnzeneX™ is an advanced fully-connected continuous manufacturing™ platform that harnesses the power of intensified perfusion using alternate tangential flow (ATF) and automated multi-column chromatography to achieve continuous production of biologics.
Designed for efficiency and cost-effectiveness, EnzeneX™ enables uninterrupted loading and processing of materials, delivering superior product quality and manufacturing outcomes.
EnzeneX™ minimizes product contact with cell culture fluid, ensuring high-quality manufacturing. This is crucial for biologics that are prone to degradation including less stable and difficult-to-express proteins.
EnzeneX™ reduces processing costs by approximately 50%, providing you with cost-effective manufacturing. This is achieved with a lower cost of goods and efficient use of resources.
EnzeneX™ provides flexibility with a minimum 30-50L supply.
The modular and variable bioreactors enable scale-on and scale-out flexibility, allowing you to adapt to changing production needs and optimize your manufacturing capacity.
EnzeneX™ increases your manufacturing productivity, achieving approximately 10 times higher productivity than traditional fed-batch manufacturing
EnzeneX™ increases sustainability by reducing the equipment footprint and carbon footprint of manufacturing processes.
Discover the science behind our patented and fully validated fully-connected continuous manufacturing™.
EnzeneX™ has enabled us to successfully manufacture commercial monoclonal antibodies (mAbs) and convert biologics from fed-batch production to FCCM™.
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.